NASDAQ:GNPX

Genprex Stock Insider Trading

Healthcare > Biotechnology

Buy GNPX

*Your capital is at risk

$0.720

-0.0153 (-2.08%)

At Close: Jun 03, 2026

Genprex Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 70.19. In total, the insiders bought 12.33M and sold 49.2K GNPX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	70.19
● Buy	12.33M shares
● Sell	49.2K shares
82% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Feb 27, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 70.19. Confidence increased due to high data reliability score of 80.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 14, 2026 Sell	Common Stock S-Sale	Longnecker Brent M Director	Director	10 Value: $12
Apr 14, 2026 Sell	Common Stock S-Sale	Longnecker Brent M Director	Director	8 Value: $10
Feb 27, 2026 Sell	Common Stock F-InKind	Confer Ryan M. President, CEO And CFO	CEO / President	9 330 Value: $18.7K
Feb 27, 2026 Sell	Common Stock F-InKind	Berger Mark Stanley Chief Medical Officer	Officer	7 168 Value: $14.3K
Dec 22, 2025 Buy	Common Stock A-Award	Wilson William R Jr. Director	Director	9 000 Value: $18.1K
Dec 22, 2025 Buy	Common Stock A-Award	Longnecker Brent M Director	Director	9 000 Value: $18.1K
Dec 22, 2025 Buy	Common Stock A-Award	Confer Ryan M. President, CEO And CFO	CEO / President	45 000 Value: $90.5K
Dec 22, 2025 Buy	Common Stock A-Award	Berger Mark Stanley Chief Medical Officer	Officer	28 500 Value: $57.3K
Dec 22, 2025 Buy	Common Stock A-Award	Moreno Toscano Jose Antonio Director	Director	9 000 Value: $18.1K
Jun 30, 2025 Sell	Common Stock F-InKind	Berger Mark Stanley Chief Medical Officer	Officer	4 500 Value: $1K
Jun 30, 2025 Sell	Common Stock F-InKind	Confer Ryan M. President, CEO And CFO	CEO / President	5 775 Value: $1K
Jun 30, 2025 Sell	Common Stock F-InKind	Confer Ryan M. President, CEO And CFO	CEO / President	5 775 Value: $1K
Jun 30, 2025 Sell	Common Stock F-InKind	Berger Mark Stanley Chief Medical Officer	Officer	4 500 Value: $1K
Feb 18, 2025 Sell	Common Stock F-InKind	Berger Mark Stanley Chief Medical Officer	Officer	585 Value: $240
Feb 18, 2025 Sell	Common Stock F-InKind	Confer Ryan M. President, CEO And CFO	CEO / President	395 Value: $162
Feb 18, 2025 Sell	Common Stock F-InKind	Confer Ryan M. President, CEO And CFO	CEO / President	395 Value: $162
Feb 18, 2025 Sell	Common Stock F-InKind	Berger Mark Stanley Chief Medical Officer	Officer	585 Value: $240
Dec 05, 2024 Buy	Common Stock A-Award	Moreno Toscano Jose Antonio Director	Director	4 750 Value: $5K
Dec 05, 2024 Buy	Common Stock A-Award	Wilson William R Jr. Director	Director	4 750 Value: $5K
Dec 05, 2024 Buy	Common Stock A-Award	Longnecker Brent M Director	Director	4 750 Value: $5K
Dec 05, 2024 Buy	Common Stock A-Award	Confer Ryan M. President, CEO And CFO	CEO / President	29 375 Value: $31.7K
Dec 05, 2024 Buy	Common Stock A-Award	Berger Mark Stanley Chief Medical Officer	Officer	18 250 Value: $19.7K
Dec 05, 2024 Buy	Common Stock A-Award	Berger Mark Stanley Chief Medical Officer	Officer	18 250 Value: $19.7K
Dec 05, 2024 Buy	Common Stock A-Award	Confer Ryan M. President, CEO And CFO	CEO / President	29 375 Value: $31.7K
Dec 05, 2024 Buy	Common Stock A-Award	Longnecker Brent M Director	Director	4 750 Value: $5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT GENPREX INC.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas....

Read Full Profile Here